Cravath’s New York Office Moves to Two Manhattan West
Andrei Harasymiak focuses on intellectual property litigation.
Mr. Harasymiak’s clients have included IBM, GlaxoSmithKline, Qualcomm, Xerox, NCR, Alarm.com, Amgen and Abiomed.
A representative list of Mr. Harasymiak’s matters includes:
Intellectual Property Litigation
Other Matters
Mr. Harasymiak was born in New York City. He received an A.B. magna cum laude from Harvard College in 1987 and a J.D. cum laude from Harvard Law School in 1994. Mr. Harasymiak joined Cravath in 1994 and was named of counsel in 2021. He is admitted to practice before the U.S. District Courts for the Eastern District of New York and the Southern District of New York and before the U.S. Court of Appeals for the Federal Circuit.
A representative list of Mr. Harasymiak’s matters includes:
Intellectual Property Litigation
Other Matters
Mr. Harasymiak was born in New York City. He received an A.B. magna cum laude from Harvard College in 1987 and a J.D. cum laude from Harvard Law School in 1994. Mr. Harasymiak joined Cravath in 1994 and was named of counsel in 2021. He is admitted to practice before the U.S. District Courts for the Eastern District of New York and the Southern District of New York and before the U.S. Court of Appeals for the Federal Circuit.
American Bar Association
Ukrainian Institute of America
Ukrainian Studies Fund, Inc.
Deals & Cases
October 17, 2024
On October 15, 2024, the United States Court of Appeals for the Federal Circuit affirmed an inter partes review (“IPR”) decision by the Patent Trial and Appeal Board (“PTAB”) in favor of Cravath client ADT Inc., invalidating all claims of a patent at issue in litigation brought by Vivint, Inc.
Deals & Cases
October 09, 2023
On September 22, 2023, the U.S. District Court for the District of Massachusetts ruled in favor of Cravath clients Abiomed, Inc. and Abiomed Europe GmbH (together, “Abiomed”), denying a motion to dismiss litigation brought by Abiomed against German defendants Enmodes GmbH and its CEO Tim Kaufmann.
Deals & Cases
January 31, 2023
In January, 2023, Cravath client Abiomed Inc. (“Abiomed”) secured a victory before the U.S. Patent Trial and Appeal Board (“PTAB”) of the United States Patent and Trademark Office (“USPTO”).
Andrei Harasymiak focuses on intellectual property litigation.
Mr. Harasymiak’s clients have included IBM, GlaxoSmithKline, Qualcomm, Xerox, NCR, Alarm.com, Amgen and Abiomed.
A representative list of Mr. Harasymiak’s matters includes:
Intellectual Property Litigation
Other Matters
Mr. Harasymiak was born in New York City. He received an A.B. magna cum laude from Harvard College in 1987 and a J.D. cum laude from Harvard Law School in 1994. Mr. Harasymiak joined Cravath in 1994 and was named of counsel in 2021. He is admitted to practice before the U.S. District Courts for the Eastern District of New York and the Southern District of New York and before the U.S. Court of Appeals for the Federal Circuit.
A representative list of Mr. Harasymiak’s matters includes:
Intellectual Property Litigation
Other Matters
Mr. Harasymiak was born in New York City. He received an A.B. magna cum laude from Harvard College in 1987 and a J.D. cum laude from Harvard Law School in 1994. Mr. Harasymiak joined Cravath in 1994 and was named of counsel in 2021. He is admitted to practice before the U.S. District Courts for the Eastern District of New York and the Southern District of New York and before the U.S. Court of Appeals for the Federal Circuit.
American Bar Association
Ukrainian Institute of America
Ukrainian Studies Fund, Inc.
Deals & Cases
October 17, 2024
On October 15, 2024, the United States Court of Appeals for the Federal Circuit affirmed an inter partes review (“IPR”) decision by the Patent Trial and Appeal Board (“PTAB”) in favor of Cravath client ADT Inc., invalidating all claims of a patent at issue in litigation brought by Vivint, Inc.
Deals & Cases
October 09, 2023
On September 22, 2023, the U.S. District Court for the District of Massachusetts ruled in favor of Cravath clients Abiomed, Inc. and Abiomed Europe GmbH (together, “Abiomed”), denying a motion to dismiss litigation brought by Abiomed against German defendants Enmodes GmbH and its CEO Tim Kaufmann.
Deals & Cases
January 31, 2023
In January, 2023, Cravath client Abiomed Inc. (“Abiomed”) secured a victory before the U.S. Patent Trial and Appeal Board (“PTAB”) of the United States Patent and Trademark Office (“USPTO”).
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.